Innovation Theaters
* These are not official programs of the American College of Rheumatology.
UCB Program: Expert Perspectives on a New Treatment
Exhibit Hall, Innovation Theater A
Developed and offered by UCB (Non-CME)
Exploring the Clinical Profile of SAPHNELO® (anifrolumab-fnia): An Expert Review of the TULIP Pivotal Trials and 4-Year Long-Term Extension Study
Exhibit Hall, Innovation Theater B
Developed and offered by AstraZeneca (Non-CME)
Understanding Early Advanced Therapy Use in Lupus: A Treatment Evolution
Exhibit Hall, Innovation Theater A
Developed and offered by GSK (Non-CME)
Conversations in Autoimmune-Associated Interstitial Lung Disease (ILD): The Patient Journey, The Physician Perspective
Exhibit Hall, Innovation Theater B
Independent medical education grant support for this session is provided by Boehringer Ingelheim Pharmaceuticals, Inc., and sponsored by Med Learning Group (Non-CME)
Tremfya in Focus: Multi-Specialty Insights From a Rheumatologist, Dermatologist, and Gastroenterologist
Exhibit Hall, Innovation Theater B
Developed and offered by Johnson & Johnson (Non-CME)
Achieving Your Treatment Goals: Consider When a Treatment Switch in RA May Be the Right Transition For Your Patients
Exhibit Hall, Innovation Theater A
Developed and offered by AbbVie (Non-CME)
A Dual Product Event: Ixekizumab and Tirzepatide
Exhibit Hall, Innovation Theater B
Developed and offered by Eli Lilly and Company (Non-CME)
Collaborative Frameworks in CAR T-Cell Therapy for Autoimmune Diseases
Exhibit Hall, Innovation Theater A
Developed and offered by Bristol Myers Squibb (Non-CME)
Real-World Solutions: The Role of Novel Biomarkers in Diagnosing SLE and RA
Exhibit Hall, Innovation Theater B
Developed and offered by Exagen (Non-CME)
Changing the Treatment Paradigm in Recurrent Pericarditis (RP): Moving Beyond an Episodic Approach
Exhibit Hall, Innovation Theater A
Developed and offered by Kiniksa Pharmaceuticals (Non-CME)
Expert Perspectives on Dual Inhibition of IL-17A + IL-17F: A Different Mechanism of Action
Exhibit Hall, Innovation Theater B
Developed and offered by UCB (Non-CME)
Achieving an Immune System RESET: The Next Act in CAR T Therapy
Exhibit Hall, Innovation Theater A
Developed and offered by Cabaletta Bio (Non-CME)
Three Rheumatologic Diseases, One FDA-Approved Option to Consider for Appropriate Patients, From Juveniles to Adults
Exhibit Hall, Innovation Theater B
Developed and offered by Sanofi Pharmaceuticals (Non-CME)
Beyond the Basics: What Makes Immunoglobulin Therapy Effective in Dermatomyositis?
Exhibit Hall, Innovation Theater A
Developed and offered by Octapharma (Non-CME)
Expert Perspectives: Identification and Management of Eosinophilic Granulomatosis with Polyangiitis
Exhibit Hall, Innovation Theater B
Developed and offered by GSK